That’s a steeper hit than the 15% to 20% range applied on several regional peers.India’s stock benchmark has lagged most major global peers this year amid concerns over a slowdown in its economy and corporate earnings.

Oil prices edged down on Thursday as investors weigh the supply risks from U.S. President Donald Trump's push for a swift resolution to the war in Ukraine through more tariffs while a surprise build in U.

Revenue up 21.7% at Rs 5,521 crore versus Rs 4,538 crore.Ebitda up 38.9% at Rs 878 crore versus Rs 632 crore.Margin at 15.9% versus 13.9%.Net Profit up 50.8% at Rs 855 crore versus Rs 567 crore.Sun Pharma Q1 Highlights (Consolidated,